CCM
BEAT

Consonance Capital Management’s BioTelemetry, Inc. BEAT Stock Holding History

Consonance Capital Management’s Portfolio BEAT Stock Details BEAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-49,219
Closed -$1.9M – 43
2020
Q1 		$1.9M Sell
49,219
-105,781
-68% -$4.87M 0.14% 30
2019
Q4 		$7.18M Buy
+155,000
New +$6.71M 0.44% 31

Other funds holding BEAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Consonance Capital Management's BEAT Position: Q2 2020 in Review

Consonance Capital Management sold out of BioTelemetry, Inc. (BEAT) in Q2 2020, closing a stake of 49,219 shares — an estimated $1.9M sold.

Consonance Capital Management first reported a position in BEAT in Q4 2019 and held it in 2 quarters. The position peaked at $7.18M in Q4 2019. 215 funds tracked by Wall St. Rank hold BEAT as of Q2 2020.

  • Consonance Capital Management reported no remaining BioTelemetry, Inc. position as of Q2 2020 after selling out during the quarter.
  • Consonance Capital Management sold 49,219 BioTelemetry, Inc. shares in Q2 2020, an estimated $1.9M.
  • Consonance Capital Management first reported a position in BioTelemetry, Inc. in Q4 2019 and held it in 2 quarters.
  • Consonance Capital Management's BioTelemetry, Inc. position peaked at $7.18M in Q4 2019.
  • 215 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q2 2020.

Based on Consonance Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.